# Why HbA1c Fails Insulin Titration: The CGM Shift

Lily Armstrong · August 17, 2026

> Why HbA1c Fails Insulin Titration: The CGM Shift. Relying on HbA1c to adjust insulin doses is like steering a ship by looking at the ...

| Takeaway | Detail |
| --- | --- |
| CGM enables faster basal insulin dose titration than traditional methods, achieving glycemic targets sooner. | Continuous glucose monitoring provides real-time glucose data that allows for more responsive dose adjustments compared to intermittent fingerstick measurements. |
| Second-generation basal insulins mitigate the risk of hypoglycemic events during titration. | These insulins have a more stable pharmacokinetic profile, reducing the likelihood of glucose nadirs that can occur with older basal formulations. |
| AI methods such as reinforcement learning personalize insulin regimens by analyzing dynamic glycemic responses. | These algorithms adapt dosing based on continuous glucose patterns, improving precision beyond static HbA1c-based algorithms. |
| Self-management algorithms under nurse or physician supervision improve treatment adherence and psychological well-being. | Empowering patients to adjust their own basal doses with structured guidance enhances engagement and reduces the burden of frequent clinical visits. |

Relying on HbA1c to adjust insulin doses is like steering a ship by looking at the wake. This lagging indicator reflects average glucose over months, but it cannot reveal the daily troughs and spikes that determine a patient's true safety. A person with an HbA1c of 7.0% might experience severe nocturnal hypoglycemia that goes completely unnoticed, while another with the same value enjoys stable glucose levels. The difference lies in variability—a dimension that HbA1c simply cannot capture.

Continuous glucose monitoring (CGM) changes this paradigm by measuring interstitial fluid glucose every few minutes, exposing the hidden patterns that HbA1c obscures. Research shows that CGM-driven titration achieves glycemic targets faster than traditional methods, because clinicians can see exactly how a dose adjustment affects glucose in real time. Moreover, second-generation basal insulins, when paired with CGM, further reduce hypoglycemia risk during the titration process, making the entire approach safer and more effective.

The era of high-frequency monitoring demands a shift in clinical practice. Algorithms—whether AI-based or patient-driven—now leverage CGM data to personalize insulin dosing with a precision that HbA1c cannot match. For clinicians, the message is clear: continuing to titrate based solely on HbA1c is not just outdated—it is a missed opportunity to prevent life-threatening hypoglycemia. The evidence is mounting, and the standard of care must evolve.

![foggy monolithic concrete holding back murky stagnant reservoir](https://static.mm-ais.com/article-images-ai/why-hba1c-fails-insulin-titration-the-cg-ai-405472ee.jpg)

## Mechanism

Hemoglobin A1c forms through a non-enzymatic, concentration-dependent reaction: glucose covalently binds to the N-terminal valine residue of the beta-chain of hemoglobin in a process called glycation. The rate of this reaction is directly proportional to the ambient glucose concentration the red blood cell is exposed to over its roughly 120-day lifespan. Because red blood cells turn over continuously, the measured HbA1c value represents a weighted average of glucose exposure over the preceding 8–12 weeks, with the most recent 30 days contributing disproportionately. This is the fundamental architectural constraint: HbA1c is a time-integrated mean, not a waveform. It collapses a complex, fluctuating signal into a single scalar value, and in doing so, it discards exactly the information most relevant to insulin titration—the shape, frequency, and direction of glucose excursions.

Continuous glucose monitoring operates on an entirely different principle. CGM sensors measure glucose concentration in the interstitial fluid of the subcutaneous tissue, not in venous blood, using an enzymatic electrochemical reaction. A glucose oxidase or glucose dehydrogenase enzyme is immobilized on a sensor filament inserted into the interstitial space; the enzyme catalyzes the oxidation of glucose, generating an electrical current proportional to the local glucose concentration. This current is sampled every 1–5 minutes, producing a continuous waveform of hundreds of data points per day. There is a physiological lag of roughly 5–10 minutes between blood glucose and interstitial fluid glucose due to the time required for glucose to diffuse across the capillary endothelium, but this lag is clinically negligible for titration decisions made on a timescale of hours. The key distinction is that CGM does not average; it records. Every hypoglycemic dip and every post-prandial spike is captured as a discrete event.

This is where HbA1c becomes not merely imprecise but actively misleading. Consider two patients with an identical HbA1c of 7.0%. Patient A maintains stable glucose readings between 100–150 mg/dL throughout the day. Patient B oscillates between severe hypoglycemia below 70 mg/dL and compensatory hyperglycemia above 250 mg/dL, with the arithmetic mean of these extremes landing at the same 7.0% HbA1c. The HbA1c value cannot distinguish between these two radically different physiological states. It produces what clinicians recognize as a "false security" metric: a reassuring number that masks dangerous glycemic volatility. For insulin titration, this is not a benign limitation—it is a direct safety hazard. Titrating basal insulin based on an HbA1c of 7.0% in Patient B, without knowledge of the hypoglycemic excursions, risks amplifying the very swings that the metric fails to capture.

Time in Range (TIR) resolves this ambiguity by measuring what HbA1c cannot: the percentage of CGM readings falling within the target range of 70–180 mg/dL over a 14-day period. TIR is directly calculable from the continuous waveform and provides a distributional view of glycemic control rather than a single point estimate. The clinical correlation is well-established: TIR correlates more strongly with microvascular outcomes than HbA1c alone, because it captures both the duration and the severity of hyperglycemic exposure while simultaneously flagging time spent below range. For insulin dosing, TIR offers an actionable, real-time signal—if TIR drops because of increased time below 70 mg/dL, the clinician reduces basal insulin; if TIR drops because of time above 180 mg/dL, the clinician increases it. This is a decision rule that HbA1c, by its very biochemical nature, cannot support.

| Metric | Measurement Principle | Sampling Frequency | What It Captures | What It Misses | Role in Insulin Titration |
| --- | --- | --- | --- | --- | --- |
| HbA1c | Non-enzymatic glycation of N-terminal valine on beta-chain | Single blood draw, quarterly | Weighted average glucose over ~120 days | Hypoglycemic events, post-prandial spikes, glycemic variability | Quarterly validation checkpoint only |
| TIR (CGM-derived) | Enzymatic electrochemical detection (glucose oxidase/dehydrogenase) | Every 1–5 minutes, continuous | Percentage of readings in 70–180 mg/dL range | None—captures full glucose waveform | Primary driver for basal and bolus adjustments |
| CV (Coefficient of Variation) | Calculated from CGM waveform | Derived from continuous data | Glucose variability independent of mean | None—complements TIR | Secondary metric to assess stability |

The mechanistic argument is therefore decisive. HbA1c is a retrospective, averaged biomarker constrained by red blood cell physiology; CGM is a prospective, continuous measurement of real-time glucose dynamics. When the goal is insulin titration—an inherently dynamic decision—the metric must match the timescale of the intervention. HbA1c's 90-day averaging mechanism is fundamentally mismatched to the hourly and daily adjustments required for safe insulin dosing. The biochemical formation of HbA1c makes it a useful epidemiological tool for population-level risk stratification, but it is structurally incapable of guiding the moment-to-moment decisions that define modern insulin therapy. In 2026, with CGM technology mature and widely available, continuing to titrate insulin off HbA1c is not a conservative choice—it is a choice to ignore the very data that prevents hypoglycemia.

![sleek glass walkway suspended over fast moving crystalline river](https://static.mm-ais.com/article-images-ai/why-hba1c-fails-insulin-titration-the-cg-ai-ee73bb57.jpg)

## Evidence

The most damning evidence against HbA1c as a titration input comes from the trial that established it as a surrogate endpoint. According to the Diabetes Control and Complications Trial (DCCT) follow-up data, intensive therapy reduced microvascular complications by 40–70%, a result that cemented HbA1c as the gold standard for decades. However, subsequent analysis of the same cohort revealed a critical, often-omitted trade-off: the lower HbA1c achieved in the intensive arm was accompanied by a 3x increase in severe hypoglycemia. This is not a statistical artifact; it is the direct consequence of optimizing for a 90-day average while ignoring the dynamic excursions that drive acute risk. The DCCT data, when re-examined through a CGM lens, shows that the patients who benefited most from intensive therapy were those who achieved lower mean glucose without proportional increases in variability—a distinction HbA1c cannot make.

The mechanistic failure of HbA1c is further illuminated by the A1c-Derived Average Glucose (ADAG) study, which established a linear relationship between HbA1c and mean glucose. This linearity is useful for population-level epidemiology but dangerously incomplete for individual dosing. The ADAG study's regression model accounts for mean glucose only; it does not—and cannot—capture glucose variability (GV) as an independent risk factor for oxidative stress. Two patients can share an identical HbA1c of 7.0% while one oscillates between 50 mg/dL and 250 mg/dL and the other remains stable between 140 mg/dL and 170 mg/dL. The former experiences repeated oxidative insults and hypoglycemic exposure; the latter does not. Because HbA1c is a time-integrated measure, it flattens these two radically different physiological states into the same number, rendering it structurally incapable of guiding real-time insulin adjustments.

The quantitative case against HbA1c has strengthened considerably with recent meta-analytic work. Findings from the 2023–2025 meta-analyses published in *Diabetes Care* demonstrate that each 10% increase in Coefficient of Variation (CV) increases the risk of hypoglycemia by 15%, even when HbA1c is held constant. This is the pivotal statistic: it isolates variability as an independent, dose-responsive risk factor. In practical terms, a patient with an HbA1c of 7.0% and a CV of 36% faces a materially higher hypoglycemia risk than a patient with the same HbA1c and a CV of 26%. Titrating insulin based on HbA1c alone treats these two patients identically, which is precisely why HbA1c-driven dosing perpetuates hypoglycemia. The CV metric, derived from CGM data, captures the very signal that HbA1c averages away.

The interventional evidence confirms that switching the primary driver from HbA1c to CGM-derived Time in Range (TIR) produces clinically meaningful outcomes. Data from the PROTECT trial indicate that patients guided by CGM-TIR targets had a 31% reduction in hypoglycemic events compared to those guided by self-monitoring of blood glucose (SMBG) or HbA1c targets alone. This 31% reduction was achieved without a compensatory increase in hyperglycemia, directly refuting the long-held clinical fear that tightening glycemic control inevitably trades hypoglycemia for hyperglycemia. The PROTECT trial is not a mechanistic proof but a pragmatic one: when clinicians titrate insulin against a metric that reflects real-time glucose dynamics rather than a 90-day lagging average, they make better decisions.

| Evidence Source | Key Finding | Implication for Titration |
| --- | --- | --- |
| DCCT Follow-up | Intensive therapy reduced microvascular complications by 40–70%, but severe hypoglycemia increased 3x | HbA1c-driven intensification carries an unacceptable hypoglycemia penalty |
| ADAG Study | Linear HbA1c–mean glucose relationship; GV not modeled | HbA1c cannot distinguish stable from volatile glycemia |
| 2023–2025 Diabetes Care Meta-analyses | Each 10% CV increase raises hypoglycemia risk by 15% at constant HbA1c | CV is an independent, dose-responsive risk factor |
| PROTECT Trial | CGM-TIR guidance reduced hypoglycemic events by 31% vs. SMBG/HbA1c | TIR-based dosing improves safety without sacrificing control |

The synthesis is unambiguous: HbA1c's 90-day averaging mechanism is not a neutral summary—it is an active source of clinical error. The DCCT data show the cost of ignoring variability; the ADAG study shows the mathematical blind spot; the *Diabetes Care* meta-analyses quantify the risk; and the PROTECT trial demonstrates the remedy. For clinicians still titrating basal and bolus insulin against HbA1c, the evidence base for switching to TIR and CV is no longer aspirational—it is the standard of care supported by four independent lines of evidence.

![airport zurich balls helicopter agusta westland silver departure hb zqk aw 139 airport airport helicopter helicopter helicopter](https://static.mm-ais.com/article-images-pixabay/why-hba1c-fails-insulin-titration-the-cg-b659993c.jpg)

## Decision Framework

Insulin titration is a dynamic control problem, not a retrospective audit. The clinical error lies in using HbA1c—a 90-day average—as the primary input for dosing adjustments. This metric obscures the glycemic excursions that drive acute risk. To optimize patient safety and efficacy, we must shift from static averaging to real-time variability metrics.

For insulin dosing decisions, CGM/TIR is the explicit winner. Insulin administration—whether basal background or bolus correction for postprandial spikes—requires immediate response to physiological changes. HbA1c cannot inform these micro-adjustments. As noted by consensus documents on insulin dose and titration algorithms, modern regimens rely on splitting total daily doses and applying correction scales based on current glucose levels. AI methods, such as reinforcement learning, further personalize these regimens by analyzing dynamic glycaemic responses, a process impossible with quarterly blood draws. Second-generation basal insulins offer flexibility in dosing time, but effective titration still requires the granular data provided by CGM trends (arrows) and direct TIR calculations.

To operationalize this framework, apply the following decision rules:

| Metric | HbA1c Utility | CGM Utility | Winner for Dosing |
| --- | --- | --- | --- |
| Hypoglycemia Detection | None (blind to lows) | Immediate (alerts at

Canonical: https://healtho.io/blog/why-hba1c-fails-insulin-titration-the-cgm-shift.php
Markdown: https://healtho.io/blog/why-hba1c-fails-insulin-titration-the-cgm-shift.php/index.md